



Practitioner's Docket No. MPI00-282P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Glucksmann, Maria A.  
Application No.: 09/896,522 Group No.: 1652  
Filed: June 28, 2001 Examiner: Swope, Sheridan  
For: 57658, A NOVEL HUMAN URIDINE KINASE AND USES THEREOF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1.  Preliminary Statements
2.  Form PTO/SB/08B (substitute for Form PTO-1449) (1 page)

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**


**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: May 4, 2004

Diana Gentile  
(type or print name of person certifying)

**Practitioner's Docket No. MPI00-282P1RM**

**Preliminary Statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.


The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

This Information Disclosure Statement is submitted solely to correct citation format in accordance with the Examiner's suggestion.

May 4, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Kerri Pollard Schray  
Registration No. 47,066  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

MAY 07 2004

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

1

Complete if Known

Application Number	09/896522
Filing Date	June 28, 2001
First Named Inventor	Glucksmann, Maria A.
Group Art Unit	1652
Examiner Name	Swope, Sheridan
Attorney Docket Number	MP100-282P1RM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A1	Corby, N., Rp11-334J6 is from the library RPCI-11.2 constructed by the group of Pieter de Jong – Human DNA sequence from clone RP11-334J6 on chromosome 9, June 8, 2000 (sequence) EMBL Sequence Library [online] Heidelberg, Germany: European Molecular Biology Laboratory, Retrieved from the internet: URL: <a href="HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?E+[EMBL-ID:AL358781]">HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?E+[EMBL-ID:AL358781]</a> EMBL Accession No. AL358781.	
	A2	Isogai, T. et al., NEDO human cDNA sequencing project – Homo sapiens cDNA FLJ12255 fis, clone MAMMA1001476, highly similar to URIDINE KINASE (EC2.7.1.48), September 29, 2000 (sequence) EMBL Sequence Library [online] Heidelberg, Germany: European Molecular Biology Laboratory, retrieved from the internet: URL: <a href="HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?E+[EMBL-ID:AK022317]">HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?E+[EMBL-ID:AK022317]</a> EMBL Accession No. AK022317.	
	A3	Univ. Fudan, Section Ch, Week 2001144, March 14, 2001, WPI database, London, GB: Derwent Publications Ltd., Class B04, WPI Accession No. 2001-409529.	
	A4	Drake, J. C. et al, "Characteristics of the enzyme uridine-cytidine kinase isolated from a cultured human cell line", <i>Biochemical Pharmacology</i> , 26(1):64-66 (January 1, 1977).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Practitioner Docket No. MPI00-282P1RM

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Glucksmann, Maria A.

Application No.: 09/896,522

Group No.: 1652

Filed: June 28, 2001

Examiner: Swope, Sheridan

For: 57658, A NOVEL HUMAN URIDINE KINASE AND USES THERE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

**Signature**

Date: May 4, 2004

Diana Gentile

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-282P1RM**

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

This Information Disclosure Statement is submitted solely to correct citation format of references previously cited in accordance with the Examiner's suggestion.

**OR**

The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A.  Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B.  Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C.  No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**Practitioner's Docket No. MPI00-282P1RM**

**FEE PAYMENT**

3.  The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00


**METHOD OF PAYMENT OF FEE**

4.  Attached is a check in the amount of \$ \_\_\_\_\_.  
 Charge Account No. 501668 in the amount of \$0.00.  
 A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

May 4, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By 

Kerri Pollard Schray  
Registration No. 47,066  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820